Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LC16m8 Vaccine for Mpox Prevention in Colombia
NCT06223919Phase 3Active, not recruiting
- Sponsor
- Universidad Nacional de Colombia
- Start
- Dec 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lc16m8 in mpox, sponsored by Universidad Nacional de Colombia. Started Dec 2023; status: active, not recruiting.
02
Drugs
lc16m8
03
Conditions
mpox
Beyond the preview
Go deeper on NCT06223919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06223919.